Q3 2023 EPS Estimates for Catalent, Inc. Decreased by William Blair (NYSE:CTLT)

Catalent, Inc. (NYSE:CTLT – Get Rating) – Research analysts at William Blair cut their Q3 2023 earnings per share (EPS) estimates for shares of Catalent in a research report issued to clients and investors on Monday, May 22nd. William Blair analyst M. Smock now anticipates that the company will post earnings per share of ($0.22) for the quarter, down from their prior estimate of $0.06. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Catalent’s current full-year earnings is $1.05 per share. William Blair also issued estimates for Catalent’s Q4 2023 earnings at $0.20 EPS, FY2023 earnings at $0.87 EPS, Q1 2024 earnings at $0.06 EPS, Q2 2024 earnings at $0.24 EPS, Q3 2024 earnings at $0.38 EPS, Q4 2024 earnings at $0.66 EPS and FY2024 earnings at $1.35 EPS.

Several other brokerages have also recently commented on CTLT. Barclays lowered their price target on Catalent from $40.00 to $35.00 in a research note on Sunday. JPMorgan Chase & Co. cut Catalent from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $90.00 to $45.00 in a research note on Sunday. Morgan Stanley reduced their target price on Catalent from $85.00 to $50.00 in a report on Monday. Robert W. Baird reduced their target price on Catalent from $53.00 to $35.00 in a report on Monday. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on Catalent from $29.00 to $37.00 in a report on Monday. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Catalent has a consensus rating of “Hold” and a consensus price target of $67.55.

Catalent Trading Down 1.8 %

NYSE:CTLT opened at $37.44 on Wednesday. The stock has a market cap of $6.74 billion, a PE ratio of 16.57, a price-to-earnings-growth ratio of 4.64 and a beta of 1.17. The stock’s 50-day moving average is $51.22 and its two-hundred day moving average is $52.92. Catalent has a fifty-two week low of $31.45 and a fifty-two week high of $115.33. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.91 and a quick ratio of 1.38.

Insider Transactions at Catalent

In other Catalent news, SVP Mario Gargiulo sold 678 shares of the company’s stock in a transaction on Monday, May 1st. The stock was sold at an average price of $49.86, for a total value of $33,805.08. Following the sale, the senior vice president now directly owns 5,676 shares in the company, valued at $283,005.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Manja Boerman sold 1,446 shares of the stock in a transaction on Monday, May 1st. The stock was sold at an average price of $49.86, for a total transaction of $72,097.56. Following the sale, the insider now owns 14,414 shares in the company, valued at $718,682.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Mario Gargiulo sold 678 shares of the company’s stock in a transaction on Monday, May 1st. The shares were sold at an average price of $49.86, for a total value of $33,805.08. Following the transaction, the senior vice president now directly owns 5,676 shares in the company, valued at approximately $283,005.36. The disclosure for this sale can be found here. Corporate insiders own 0.58% of the company’s stock.

Hedge Funds Weigh In On Catalent

Several large investors have recently made changes to their positions in CTLT. Itau Unibanco Holding S.A. lifted its stake in Catalent by 372.7% in the third quarter. Itau Unibanco Holding S.A. now owns 3,134 shares of the company’s stock valued at $227,000 after buying an additional 2,471 shares during the period. Empirical Finance LLC grew its holdings in shares of Catalent by 25.0% during the third quarter. Empirical Finance LLC now owns 3,644 shares of the company’s stock worth $264,000 after buying an additional 728 shares in the last quarter. Inspire Investing LLC grew its holdings in shares of Catalent by 12.1% during the fourth quarter. Inspire Investing LLC now owns 25,647 shares of the company’s stock worth $1,154,000 after buying an additional 2,775 shares in the last quarter. Asset Management One Co. Ltd. grew its holdings in shares of Catalent by 1.3% during the third quarter. Asset Management One Co. Ltd. now owns 74,710 shares of the company’s stock worth $5,406,000 after buying an additional 952 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Catalent by 313.9% during the third quarter. Tower Research Capital LLC TRC now owns 49,717 shares of the company’s stock worth $3,597,000 after buying an additional 37,706 shares in the last quarter. Institutional investors and hedge funds own 99.38% of the company’s stock.

About Catalent

(Get Rating)

Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.